The role of inflammatory mediators in severe acute pancreatitis and regulation of glucocorticoids

Hepatobiliary and Pancreatic Diseases International

Volumn 2, Issue 3, 2003, Pages 458-462

  Wang, Zi Fa ^a,b   Pan, Cheng En ^a   Lu, Yi ^a   Liu, Shab Gao ^a   Zhang, Guan Jun ^a   Zhang, Xue Bin ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Acute pancreatitis; Dexamethasone; Inflammatory mediators

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; AUTACOID; DEXAMETHASONE; GLUCOCORTICOID; INTERLEUKIN 6; TAUROCHOLIC ACID; THROMBOXANE B2;

ACUTE PANCREATITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE DUCT; BLOOD LEVEL; BLOOD SAMPLING; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; MALE; MORPHOLOGY; NONHUMAN; PANCREAS DUCT; PANCREAS HEMORRHAGE; PANCREAS NECROSIS; POSTOPERATIVE PERIOD; RAT; RAT STRAIN; SURVIVAL; SURVIVAL RATE; TIME; TISSUE SECTION; TREATMENT OUTCOME;

6-KETOPROSTAGLANDIN F1 ALPHA; ACUTE DISEASE; ANIMALS; ARACHIDONIC ACID; DEXAMETHASONE; GLUCOCORTICOIDS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; MALE; PANCREATITIS, ACUTE NECROTIZING; RATS; RATS, WISTAR; SURVIVAL RATE; THROMBOXANE B2;

EID: 0041911070     PISSN: 14993872     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Kingsnorth A. Role of cytokines and their inhibitors in acute pancreatitis. Gut 1997;40:1-4.
2. Kusske AM, Rongione AJ, Reder HA. Cytokines and acute pancreatitis. Gastroenterology 1996;110:639-642.
3. Norman J, Fink G, Franz M, et al. Systemic cytokines gene expression induced by acute pancreatitis. Gastroenterology 1995;108(Suppl a):1236.
4. Mckay CJ, Gallagher G, Brooks B, et al. Increased monocyte cytokine production in association with systemic complication in acute pancreatitis. Br J Surg 1996;83:919-923.
5. Uhl W, Schrag HJ, Schmitter N, et al. Experimental study of a novel phospholipase A2 inhibitor in acute pancreatilis. Br J Surg 1998;85:618-623.
6. Uhl W, Schrag HJ, Schmitter N, et al. Pathophysiological role of secretory type I and II phospholipase A2 in acute pancreatitis: an experimental study in rats. Gut 1997;40:386-392.
7. Abe T, Shimsegawa, T, Satoh A, et al. Nitric oxide modulate pancreatic edema formation in rat caerulein-induced pancreatitis. J Gastroenterol 1995;30:636-642.
8. de Beaux AC, Goldie AS, Ross JA, et al. Serum concentrations of inflammatory mediators related to organ failure in patients with acute pancreatitis. Br J Surg 1996;83:349-353.
9. Schmidt J, Lewandrowsi K, Warshaw A, et al. Morphometrics characteristics and homogeneity of a new model of acute pancreatitis in the rats. Int J Pancreatol 1992;12:41-51.
10. Closa D, Rossell CJ, Martrat C, et al. Changes of systemic procacyclins and thromboxaneA2 in sodium taurocholate and cerulein-induced pancreatitis in rats. Dig Dis Sci 1993;38:33-38.
11. Osman MO, Kristensen JU, Jacobsen NO, et al. A monoclonal anti-interleukin 8 antibody (WS-4) inhibits cytokine response and acute lung injury in experimental severe acute necrotizing pancreatitis in rabbits. Gut 1998;42:232-239.
12. McKay CJ, Curran F, Sharples C, et al. Prospective placebo-controlled randomized trial of lexipafant in predicted severe acute pancreatitis. Br J Surg 1997; 84:1239-1243.
13. Kusske AM, Rongione AJ, Ashley SW, et al. Interleukin-10 prevents death in lethal necrotizing pancreatitis in mice. Surgery 1996;120:284-288.
14. Norman J, Franz M, Fink G, et al. Decreased mortality of severe acute pancreatitis following proximal cytokines blockade. Ann Surg 1995;221:625-631.
15. Hughes CB, Grewal HP, Gaber LW, et al. Anti-TNF- α therapy improves survival and ameliorates the pathophysiology sequelae in acute pancreatitis in the rat. Am J Surg 1996;171:274-280.
16. Kingsnorth AN, Galloway SW, Formela PJ, et al. Randomized double blind phase trial of lexipafant, a platelet-activating factor antagonist, in human acute pancreatitis. Br J Surg 1995;82:1414-1420.
17. Grewal HP, Mohey EL, Din A, et al. Amelioration of the physiologic and biochemical changes of acute pancreatitis using an anti-TNF-alpha polyclonal antibody. Am J Surg 1994;167:214-218.
18. Johnson CD, Kingsnorth AN, Imrie CW, et al. Double blind, randomized, placebo controlled study of a platelet activating factor antagonist, lexipafant, in the treatment and prevention of organ failure in predicted severe acute pancreatitis. Gut 2001;48:62-69.
19. Santos AA, Scheltinga MR, Lynch E, et al. Elaboration of interleukin 1-receptor antagonist is not attenuated by glucocorticoids after endotoxemia. Arch Surg 1993;128:138-143.
20. Zanker B, Walz G, Wieder KJ, et al. Evidence that glucocorticosteroids block expression of the human interleukin-6 gene by accessory cells. Transplantation 1990;49:183-185.
21. Yao XL, Cowan MJ, Gladwin MT, et al. Dexamethasone alters arachidonate release from human epithelial cells by induction of p11 protein synthesis and inhibition of phospholipase A2 activity. J Biol Chem 1999; 274:17202-17208.
22. Dolan-O'keefe M, Nick HS. Inhibition of cytoplasmic phospholipase A2 expression by glucocorticoids in rat intestinal epithelial cells. Gastroenterology 1999;116: 855-864.
23. Hardman JG, Linbird LE. Goodman and Gilman's the pharmacological basis of therapeutics. Ninth edition. New York: McGraw-Hill. 1996,1465-1481.
24. Uhl W, Schrag HJ, Schmitter N, et al. Experimental study of a novel phospholipase A2 inhibitor in acute pancreatitis. Br J Surg 1998;85:618-623.
25. Folch E, Prats N, Hotter G, et al. P-selectin expression and Kupffer cell activation in rat acute pancreatitis. Dig Dis Sci 2000;45:1535-1544.
26. Norman J. The role of cytokines in the pathogenesis of acute pancreatitis. Am J Surg 1998;175:76-83.
27. Sandoval D, Gukovskaya A, Reavey P, et al. The role of neutrophils and platelet-activating factor in mediating experimental pancreatitis. Gastroenterology 1996; 111:1081-1091.
28. Pezzilli R, Billi P, Miniero R, et al. Serum interleukin-6, interleukin-8, and beta 2-microglobulin in early assessment of severity of acute pancreatitis. Comparison with serum C-reactive protein. Dig Dis Sci 1995; 40:2341-2348.
29. Inagaki T, Hoshino M, Hayakawa T, et al. Interleukin-6 is a useful marker for early prediction of the severity of acute pancreatitis. Pancreas 1997;14:1-8.
30. Hughes CB, Gaber LW, Mohey el-Din AB, et al. Inhibition of TNF alpha improves survival in an experimental model of acute pancreatitis. Am Surg 1996;62:8-13.
31. Windsor ACJ, Mullen PG, Walsh CJ, et al. Delayed tumor necrosis factor a blockade attenuates pulmonary dysfunction and metabolic acidosis associated with experimental gram-negative sepsis. Arch Surg 1994;129:80-89.
32. Norman JG, Franz M, Messina J, et al. Interleukin-1 receptor antagonist decreases severity of experimental acute pancreatitis. Surgery 1995;117:648-655.
33. Guice K, Oldham KT, Remick DG, et al. Anti-tumor necrosis factor antibody augments edema formation in caerulein-induced acute pancreatitis. J Surg Res 1991; 51:495-499.
34. Norman JG, Fink GW, Denham W, et al. Tissue-specific cytokine production during experimental acute pancreatitis: a probable mechanism for distant organ dysfunction. Dig Dis Sci 1997;42:1783-1788.
35. Abe R, Shimosegawa T, Kimura K, et al. The role of endogenous glucocorticoids in rat experimental models of acute pancreatitis. Gastroenterology 1995;109:933-943.
36. Osman MO, Jacobsen NO, Kristensen JU, et al. Beneficial effects of hydrocortisone in a model of experimental acute pancreatitis. Dig Surg 1999;16:214-221.
37. Gloor B, Uhl W, Tcholakov O, et al. Hydrocortisone treatment of early SIRS in acute experimental pancreatitis. Dig Dis Sci 2001;46:2154-2161.
38. Gomez G, Townsend CMJ, Green D, et al. Involvement of cholecystokinin receptors in the adverse effect of glucocorticoids on diet-induced necrotizing pancreatitis. Surgery 1989;106:230-238.